Log in to search using one of your social media accounts:

 

JAK2 V617F Acute Lymphoblastic Leukemia Secondary to Myeloproliferative Neoplasms (MPNs) or After Lenalidomide Exposure: Case Report and Review of the Literature
MPNs almost always transform to acute myeloid leukemia (AML). Delhommeau and colleagues studied the presence of the JAK2 V617F mutation in circulating B-, T- and natural killer (NK) cells of patients with PV and PMF, and detected it in B- and NK cells from approximately half their patients with PMF and a minority of those with PV. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ahmad Alhuraiji, Kiran Naqvi, Yang O. Huh, Coty Ho, Srdan Verstovsek, Prithviraj Bose Source Type: research

Our Experience in the Treatment of Adult Lymphoblastic Leukemia (including Adult T-Cell Leukemia/Lymphoma) with German Multicenter ALL (GMALL) Protocol
acute lymphoblastic leukemia, chemotherapy, minimal residual disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Smbat Daghbashyan, Zhenya Nargizyan Source Type: research

Efficacy and Safety of Defibrotide to Treat Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Primary Chemotherapy: A Post Hoc Analysis of Final Data From an Expanded-Access Protocol
VOD/SOS, which may be unpredictable and potentially life-threatening, is typically considered a complication of hematopoietic stem cell transplantation (HSCT); VOD/SOS with multi-organ dysfunction (MOD) post-HSCT may be associated with>80% mortality. Defibrotide is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the US, and to treat severe hepatic VOD/SOS post-HSCT in the EU. However, VOD/SOS also can occur after chemotherapy without HSCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nancy Kernan, Joseph Antin, Yoav Messinger, Wei Liang, Robin Hume, William Tappe, Paul Richardson Source Type: research

Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial
Older patients with ALL are often intolerant to intensive chemotherapy and have poor outcomes. We hypothesized that combination of low-intensity chemotherapy with anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (InO) may improve outcomes in the frontline setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Susan O'Brien, Farhad Ravandi, Nicholas Short, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Koji Sasaki, Naveen Pemmaraju, Yesid Alvarado, Jovitta Jacob, Rebecca Ga Source Type: research

Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
Chemoimmunotherapy with hyper-CVAD is an effective frontline regimen for ALL. Ofatumumab potently binds to CD20 with better in vitro activity than rituximab. We hypothesized that addition of ofatumumab (O) to hyper-CVAD may improve outcomes in CD20+ ALL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Maria Khouri, Guillermo Garcia-Manero, Rebecca Garris, Jorge Cortes, Nicholas Short, Koji Sasaki, Ghayas Issa, Paul Koller, Heather Schroeder, Tapan Kadia, Srdan Verstovsek, Naval Daver, Ni Source Type: research

Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
Chemotherapy in combination with tyrosine kinase inhibitors (TKI) are effective in Ph+ ALL. Ponatinib is a third-generation TKI which potently inhibits the BCR-ABL tyrosine kinase. Single-agent ponatinib has high activity in patients with Ph+ ALL but has dose-dependent cardiovascular toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Farhad Ravandi, Nicholas Short, Naval Daver, Naveen Pemmaraju, Deborah Thomas, Musa Yilmaz, Tapan Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia-Manero, Courtney DiNardo, Marina Konopleva, Zeev Estrov, Nitin Jain, W Source Type: research

Expression of CD 123 in Acute Lymphoblastic Leukemia and its Prognostic Impact
CD123 expression on blast cells and its prognostic value in acute leukemia as acute lymphoid leukemia (ALL) is a matter under investigation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Taghreed Kamal Eldin, Eman M. Nagiub Abdelsalam, Ghadeer Abdel Razak, Howaida Nafady, Mostafa F. Mohammed Saleh Source Type: research

Identifying Transcription Factors that Dictate Drug-Resistance in Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy and although approximately 98% of children enter complete remission within 6 weeks of standard chemotherapy regimens, 20% of children will relapse and approximately half relapse with drug resistant ALL. Dexamethasone and prednisone are glucocorticoids used in the treatment of pediatric blood cancers for over 50 years. The efficacy of glucocorticoid receptor modulation is well established in ALL but the response remains heterogeneous and limited by emergence of drug resistance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ninad Walavalkar, Nancy Lee, Michael Guertin Source Type: research

Interaction between Acute Lymphoblastic Leukemia Cells and Its Microenvironment
Residence and interaction with a specialized bone marrow microenvironment is important for self-renewal and differentiation of hematopoietic stem cells. While prior studies have revealed a key role of bone marrow niche in the initiation and progression of myeloid malignancies, the role of microenvironment in propagation and therapeutic response of acute lymphoblastic leukemia (ALL) is not well known. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hiroki Yoshihara, Michelle Churchman, Charles Mullighan Source Type: research

Interaction of Leukemia and Bone Marrow Microenvironment in Mouse ALL Model is Associated with Disorganized Vasculature and Progressive Hypoxia
In this study, we aimed to characterize the time-dependent progression of BM hypoxia involving both acute lymphocytic leukemia (ALL) cells and components of the BM niche, using multiphoton intravital microscopy (MP-IVM) and spectroscopic photoacoustic (PA) imaging. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Karine Harutyunyan, Marina Konopleva, Saradhi Mallampati, Mateusz Rytelewski, Tomasz Zal, Cayla Wood, Richard Bouchard Source Type: research

Adult Acute Lymphoblastic Leukemia and the Role of Stem Cell Transplantation: Real-World Data from an Urban Hospital
To determine which risk factors and/or interventions predicted relapse in high-risk adult acute lymphoblastic leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mojtaba Akhtari, Pete Pow-anpongkul Source Type: research

Management of Important Adverse Events Associated with Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Inotuzumab ozogamicin (InO) is an anti-CD22 antibody-calicheamicin conjugate being investigated in patients with acute lymphoblastic leukemia (ALL). The phase 3 INO-VATE study demonstrated superior efficacy of InO compared with standard therapy among adult patients with relapsed or refractory ALL (NCT01564784; doi: 10.1056/NEJMoa1509277). Overall tolerability of InO was confirmed, but several clinically important adverse events (AEs) associated with InO were identified, including neutropenia, thrombocytopenia, infusion-related reactions, tumor lysis syndrome, prolonged QT syndrome, and veno-occlusive disease (VOD). (Source...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Partow Kebriaei, Koen van Besien, Corey Cutler, Marcos de Lima, Sergio Giralt, Stephanie Lee, David Marks, Akil Merchant, Wendy Stock, Matthias Stelljes Source Type: research

CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
CTL019 is an investigational therapy whereby autologous T cells are genetically engineered with a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant B cells. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Karen Thudium Mueller, Edward Waldron, Stephan A. Grupp, John Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael Boyer, Keith August, Jason Hamilton, Rakesh Awasthi, Denise Sickert, Abhijit Chakraborty, Bruce L. Levine, Carl H. June, Lori Tomassia Source Type: research

In Adult Acute Lymphoblastic Leukemia End of Induction MRD Correlates Strongly with Subsequent Key Timepoints and Predicts Long Term Outcome
End of induction minimal residual disease (EOI MRD) is among the best outcome predictors in pediatric ALL and should therefore be investigated in adult ALL. 
 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Elena Maino, Arianna Masciulli, Tamara Intermesoli, Orietta Spinelli, Chiara Pavoni, Manuela Tosi, Ernesta Audisio, Chiara Cattaneo, Monica Fumagalli, Vincenzo Cassibba, Daniele Mattei, Claudio Romani, Agostino Cortelezzi, Fabio Ciceri, Anna Maria Scattol Source Type: research

Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis
We report an updated analysis from the first multicenter, global, pivotal registration trial of CAR T-cell therapy (ELIANA; NCT02435849). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jochen Buechner, Stephan A. Grupp, Shannon L. Maude, Michael Boyer, Henrique Bittencourt, Theodore W. Laetsch, Peter Bader, Michael R. Verneris, Heather Stefanski, Gary Douglas Myers, Muna Qayed, Michael A. Pulsipher, Barbara De Moerloose, Hidefumi Hirama Source Type: research

Modeling B Cell Acute Lymphoblastic Leukemia (B-ALL) with Zebrafish
Animal models are an important platform for both the biologic study of and development of drugs against the genetic drivers of cancer. Zebrafish have been proven to be an attractive animal model with T-ALL models, but currently no stable zebrafish B-ALL models exist due to a scarcity of validated zebrafish B cell specific genetic regulatory elements to drive oncogenes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: David Mangum, Sarah Rothschild, Wilson Clements Source Type: research

A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL
Outcomes of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients are poor. Inotuzumab ozogamicin (IO) is a CD22-monoclonal antibody bound to a toxin, calicheamicin. IO has single-agent activity in R/R ALL with an 80% response rate and median survival of 7.7 months. Adding IO to low-intensity chemotherapy might improve outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Rita Assi, Hagop Kantarjian, Farhad Ravandi, Susan Mary O'Brien, Partow Kebriaei, Nicholas J. Short, Deborah A. Thomas, Guillermo Garcia-Manero, Richard E. Champlin, Tapan M. Kadia, Jorge E. Cortes, Nitin Jain, Marina Konopleva, Rita Khouri, Zeev Estrov, Source Type: research

Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia
Blinatumomab is a bispecific anti-CD3/CD19 monoclonal antibody with single-agent activity in relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), independent of BCR-ABL1 mutational status, including T315I. The combination of blinatumomab with a tyrosine kinase inhibitor (TKI) may further improve outcomes with higher eradication of minimal residual disease (MRD) and lesser use of chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Rita Assi, Hagop Kantarjian, Nicholas J. Short, Naval Daver, Koichi Takahashi, Guillermo Garcia-Manero, Courtney DiNardo, Rita Khouri, Jan Burger, Nitin Jain, William Wierda, Salim Chamoun, Marina Konopleva, Elias Jabbour Source Type: research

Deep Analytical Characterization of a BCR-ABL1 minor Breakpoint (e1a2) Multiplex Assay (QuantideX qPCR BCR-ABL minor Kit) using a Background of Human RNA Reference Material
Quantitation of BCR-ABL1 minor breakpoint for CML and B-ALL research and clinical monitoring both require a highly optimized assay with well characterized analytical limits. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Michael Dodge, Ion Beldorth, Stela Filipovic-Sadic, Keri Masson, Marie Fahey, John Hedges, Justin Brown Source Type: research

Minimal Residual Disease Analysis and its Impact after Hematopoietic Stem Cell Transplant for Acute Leukemias
The presence of minimal residual disease (MRD) at the time of Hematopoietic stem cell transplantation (HSCT) is well recognized as an adverse risk factor for poor outcomes in ALL and AML patients in morphologyc remission. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Caroline Bernardi, Aruana Legnani, Vaneuza Funke, Daniela Setubal, Michel Oliveira, Samir Nabhan, Caroline Bonamin, Marco Bittencout, Ricardo Pasquini, Mariester Malvezzi, Ana Paula Azambuja Source Type: research

Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Liposomal vincristine is designed to reduce neurotoxicity and increase dose intensity delivery. Replacement of regular vincristine with liposomal vincristine might lead to improve outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Susan O'Brien, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Evguenia Gachimova, Rebecca Garris, Jorge Cortes, Hagop Kantarjian Source Type: research

Nutritional Status and Clinical Outcome in Pediatric Patients with Acute Lymphoblastic Leukemia in a Single Cancer Center in Brazil
Acute Lymphoblastic Leukemia (ALL) is the most common neoplasm in pediatric population and studies have shown that nutritional status in this group is an important prognostic factor. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marcia Schramm, Ana Lucia Carvalho, Leonardo Murad, Dan úbia Saraiva Source Type: research

High Frequency of High Risk CNAs in our Cohort of Pediatric B-ALL is Associated with Poor MRD and EFS: Data from a Tertiary Care Centre of India
Studies on genomic and sub-genomic alterations in ALL have shown promising results in correlating poor prognosis and survival in leukemia patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Minu Singh, Prateek Bhatia, Amita Trehan, Neelam Verma, Manupdesh Singh Sachdeva, Deepak Bansal, Richa Jain Source Type: research

The Incidence and Age Distribution of Leukemias in Armenia: A Population-Based Study
Leukemias are neoplastic proliferations of haematopoietic cells and form a major proportion of hematologic malignancies that are diagnosed worldwide. The information on incidence patterns of leukemias in developing countries is limited. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jemma Arakelyan, Liana Avetisyan, Diana Andreasyan, Arevik Torosyan, Lilit Sargsyan, Lusine Hakobyan, Samvel Iskanyan, Samvel Bardakchyan, Sergey Mkhitaryan, Ruzanna Papyan, Armen Tananyan, Gevorg Tamamyan Source Type: research

Are the Minimal Residual Disease Status and IKZF1 Mutations Play Prognostic Role in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Treated by RALL Protocols?
Philadelphia –positive acute lymphoblastic leukemia (Ph-positive ALL) have a poor prognosis. Some adverse prognostic features have lost clinical importance with recent improvements in therapy, other such features remain associated with worse outcomes. Different treatment approaches discriminate different risk factors. Molecular factors are researched now as a prognostic. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Olga Gavrilina, Galina Baskhaev, Bella Biderman, Ksenia Zarubina, Vera Troitskaya, Andrey Sudarikov, Hunan Julhakyan, Elena Parovichnikova Source Type: research

Evaluation of CD 25 (IL2 Receptor Alpha) Expression in Adult Acute Lymphoblastic Leukemia Patients
Acute lymphoblastic leukemia (ALL) in which 80-85% of ALL are of B-cell lineage (B-cell precursor ALL), and 15-20% are of T-cell lineage (T-ALL) .The IL-2 Receptor (IL-2R) α subunit has low affinity for its ligand but has the ability (when bound to the β and ϒ subunit) to increase the IL-2R affinity 100-fold. Heterodimerization of the β and ϒ subunits of IL-2R is essential for the signalling in T cells. Our study performed a detailed assessment of the clinical im plications and the prognostic value of the CD25. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Rasha Magdy Mohammed Said, Inas Ahmed Asfour, Gihan Mohamed Kamal Shams El Din, Entessar Mabrook Juadam Source Type: research

MTHFR C677T Polymorphism Screening: A Challenge in Acute Lymphoblastic Leukemia
Genotyping of MTHFR polymorphism is a challenge for personalized medicine in acute lymphoblastic leukemia(ALL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Rim Frikha, Tarek Rebai Source Type: research

Use of Bortezomib in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
Treating relapsed /refractory pediatric acute lymphoblastic leukemia (ALL), in developing countries, is a challenge. Novel options with reasonable efficacy /toxicity profile are needed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Adriana Bello, Rossana Cortez, Maylu Collazo Source Type: research

Extra Medullary Relapse post Allogenic Stem Cell Transplantation Tends to Occur Late, Patients have a Better Chance of Receiving a Second Transplant with Better Outcomes
Acute myeloid leukemia (AML) relapse after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) remains a significant cause of mortality and morbidity. Bone marrow Relapse is the most frequent presentation. Extra Medullary Relapse (EMR) is less common, the incidence of EMR in the literature ranges from 0.65% up to 41%. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mona Hassanein, Ghada Elgohary, Noura Alhashim, Maamoun Alsermani, Muhned Alhumaid, Syed Osman Ahmed, Feras Alfraih, Mahmoud Aljurf, Fahad Almohareb, Fahad Alsharif, Hazzaa Alzahrani, Naeem Chaudhri, Amr Hanbali, Shahrukh Hashmi, Mohamed Said, Waleed Rash Tags: Acute Myeloid Leukemia Source Type: research

Dry Beriberi, an Unusual Complication of Acute Myeloid Leukemia
Beriberi is a rare disease caused by thiamine (vitamin B1) deficiency. There are two types: dry beriberi affecting the neurologic system and wet beriberi leading to high cardiac output heart failure. In extreme cases, brain damage may occur: Wernicke-Korsakoff syndrome. The most common risk factors for thiamine deficiency are: alcohol abuse, overt malnutrition, gastric bypass surgery, total parenteral nutrition (TPN), chronic dialysis, and cancer related cachexia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Georges El Hachem, Nabil Chamseddine Source Type: research

Arsenic Overcomes Retinoic Acid-Resistance Conferred by FLT3-ITD in a Mouse Model of Acute Promyelocytic Leukemia (APL)
Experiments in mouse models have demonstrated that PML/RARA degradation is primary to the cure of APL with retinoic acid (RA) or arsenic (As). FLT3-ITD mutation occurs in 40% of APL cases and may confer a poorer prognosis. Reports suggest that adding As to patients ’ treatment may abrogate this adverse effect. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ramy Rahm é, Cécile Esnault, Hugues de Thé Source Type: research

Results of Second Salvage Therapy for Acute Myeloid Leukemia in the Modern Era
Most published studies analyze the results of salvage therapies in primary refractory or first salvage (S1) AML patients only. Several novel agents and strategies are under evaluation for potential approval in the second-salvage (S2) setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aron Simkins, Courtney D. DiNardo, Tapan Kadia, Naval Daver, Naveen Pemmaraju, Kiran Naqvi, Maro Ohanian, Koichi Takahashi, Yesid Alvarado, Mark Brandt, Sherry Pierce, Marina Konopleva, Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi- Source Type: research

Diagnostic and Prognostic Value of CD123 in Acute Myeloid Leukemia (AML)
Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative character of leukemic cells. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Taghreed Kamal Eldin, Eman M. Nagiub Abdelsalam, Ghadeer Abdel Razek, Howaida Nafady, Mostafa F. Mohammed Saleh Source Type: research

Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML)
AML, FLT3-ITD, dual MEK1-FLT3 inhibitor, peptidic CXCR4-antagonist, leukemia-stroma interactions (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Seemana Bhattacharya, Hong Mu, Sujan Piya, Weiguo Zhang, Teresa McQueen, Linda Paradiso, Galia Oberkovitz, Eyal Benami, Michael Andreeff, Gautam Borthakur Source Type: research

Genomic Landscape of Mixed Phenotype Acute Leukemia (MPAL)
Mixed phenotype acute leukemia (MPAL) is a rare subgroup of acute leukemia characterized by blasts that show immunophenotypes of both myeloid and lymphoid lineages. It poses significant diagnostic and therapeutic challenges in clinic, yet genetic basis of MPAL is not well understood. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Kiyomi Morita, Feng Wang, Keyur Patel, Carlos Bueso-Ramos, Abdallah Abou Zhar, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Jianhua Zhang, Xingzhi Song, Marisela Mendoza, Chang-Jiun Wu, Steven Kornblau, Courtney DiNardo, Source Type: research

CG ′806, a First-in-Class FLT3/BTK Inhibitor, Exerts Superior Potency against AML Cells Harboring ITD, TKD and Gatekeeper Mutated FLT3 or Wild-Type FLT3
FLT3 is widely accepted as a prime target for acute myeloid leukemia (AML) therapy. However, targeted therapy using current available FLT3 inhibitors only achieved limited clinical efficacy in mono-therapy. Acquired mutations of FLT3, including D835 or “gatekeeper” F691 mutations, have been identified in clinical patients who showed resistance/relapse to the inhibitors. CG’806 is a small molecule multi-kinase inhibitor against FLT3 and BTK kinases that is under development to treat FLT3-driven AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Weiguo Zhang, Hongying Zhang, Andrea Local, Wiliam Rice, Charlie Ly, Guopan Yu, Stephen Howell, Michael Andreeff Source Type: research

Defining Acute Myeloid Leukemia Ontogeny in Older Patients
The primary objective of this study was to validate the use of somatic mutations to determine AML ontogeny in the elderly population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Megan Melody, David Sallman, Najla AlAli, Hanadi Ramadan, Ling Zhang, Eric Padron, Kendra Sweet, Martine Extermann, Alan List, Jeffery Lancet, Rami Komrokji Source Type: research

Survival Time is Problematic as an Indicator of an anti- AML Drug ’s Effectiveness
“Complete response” (CR) in AML was originally recognized as a distinct response when because people who met the criteria for CR (ANC> 1,000, platelet count> 100,000, marrow with (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Carole Shaw, Shelly Hager, Mary-Elizabeth Percival, Roland Walter, Pamela Becker, Kathleen Shannon-Dorcy, Elihu Estey, Kelda Gardner Source Type: research

Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Stem Cell Transplantation (HSCT): Final Data from an Expanded-Access Protocol
VOD/SOS is an unpredictable, potentially life-threatening complication of conditioning regimens for HSCT; VOD/SOS with multi-organ dysfunction (MOD) may be associated with>80% mortality. Defibrotide is approved to treat hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the US and to treat severe hepatic VOD/SOS post-HSCT in the EU. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Paul Richardson, Angela Smith, Joseph Antin, Leslie Lehmann, Sergio Giralt, Wei Liang, Robin Hume, William Tappe, Nancy Kernan Source Type: research

Day+100 Survival and Safety Results from a Defibrotide Expanded-Access Program for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): Final Results
VOD/SOS is a potentially life-threatening complication of hematopoietic stem cell transplant (HSCT) conditioning or chemotherapy; VOD/SOS with multi-organ dysfunction (MOD) may be associated with>80% mortality. Defibrotide is approved for treating hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the US, and for treating severe hepatic VOD/SOS post-HSCT in the EU. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nancy Kernan, Angela Smith, Joseph Antin, Leslie Lehmann, Sergio Giralt, Robert Ryan, Robin Hume, William Tappe, Paul Richardson Source Type: research

Trial in Progress: A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
Lintuzumab-Ac225 is a radioimmunoconjugate composed of 225Ac (t ½=10 days), which emits 4 α-particles, linked to a humanized anti-CD33 monoclonal antibody. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Joseph G. Jurcic, Moshe Levy, Jae Park, Farhad Ravandi, Alexander Perl, John Pagel, B. Douglas Smith, Johnnie Orozco, Elihu Estey, Hagop Kantarjian, David Scheinberg, Laura Finn, Sharif Khan, Gerhard Hildebrandt, Michael Craig, Ehab Atallah, Irma Molina, Source Type: research

Acute Anthracycline Induced Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation
Anthracyclines remain the cornerstone of therapy for a wide spectrum of malignancies and have markedly improved survival of patients with acute myeloid leukemia (AML). There is scarce data regarding the acute cardiotoxic effects of anthracyclines in AML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Oren Pasvolsky, Olga Morelli, Uri Rozovski, Moti Vaturi, Ofir Wolach, Irina Amitai, Iuliana Vaxman, Roy Ratzon, Moshe Yeshurun, Zaza Iakobishvilli, Ran Kornowski, Pia Raanani Source Type: research

MRD Status and its Prognostic Significance in High-Risk AML Patients: A Single Center Experience
Minimal residual disease plays a pivotal role in clinical decision-making and treatment tailoring in acute lymphoblastic leukemia1. Conversely, the prognostic significance of MRD and its clinical usefulness in the management of acute myeloid leukemia patients is still debated. While MRD status seems to add clinically useful information in favorable and intermediate-risk patients2, its role in high cytogenetic risk patients is much less defined. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Matteo Piccini, Arianna Fani Source Type: research

Phase 2, Randomized, Double-Blind, Placebo Controlled Study of Inecaclcitol Combined with Decitabine versus Decitabine: A New Treatment Strategy for Elderly AML Patients Unfit for Intensive Chemotherapy
Leukemogenesis is a multistep process with mutations conferring an advantage in proliferation and others leading to a blockade of maturation. Available treatments are targeting proliferation. Vitamine D is a differentiating agent acting through the Vitamin-D Receptor (VDR). AML patients ’ prognosis is correlated to VDR expression. Promoter of VDR is highly methylatded in AML cells and limits transcriptional responsiveness of VDR. This could explain the disappointing results from previous clinical trials of vitamin D. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Olivier Hermine, Jean Francois Dufour-Lamartinie, Stephanie Renaux, Jorge Cortes Source Type: research

Aqueous Urtica Dioica Leaves Extract Inhibits Proliferation of Acute Myeloid Leukemia Cells in Vitro
AML, considered as the most common type of leukemia, is characterized by the dysregulation between alive and dead cells, due to either alteration in tumor suppressor genes or activation of oncogenes, resulting in the accumulation of immature cells in the bone marrow. Urtica dioica (UD) is known to have various pharmacological activities as anti-bacterial, anti-inflammatory and anti-cancerous. The aim of this study is to examine the effect of aqueous leaves extract on the proliferation of U937 cell line. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sandra Rizk, Nour Al Bast, Mohammad H. Hodroj, Jamilah Borjac Source Type: research

Receipt of Initial Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia (AML)
The use of chemotherapy can improve quality of life and survival in AML; however, many newly diagnosed patients do not receive any chemotherapy. Non-biological factors may influence the utilization of chemotherapy and can impact quality of care. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Vijaya Bhatt, Valerie Shostrom, Krishna Gundabolu Source Type: research

A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated On versus Off Study
Participation in clinical trials is recommended for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who are treated with intensive induction therapy, but enrollment is often challenging. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mary-Elizabeth Percival, Sarah Buckley, Megan Othus, Anna Halpern, Emily Huebner, Pamela Becker, Carole Shaw, Mazyar Shadman, Roland Walter, Elihu Estey Source Type: research

Detection of Leukemia-Associated Immunophenotypic Profiles at Variable Frequencies in Healthy Donors Bone Marrow Specimens
The identification of leukemia-specific immunophenotypic profiles (LAIPs) constitutes the fundament of minimal residual disease monitoring by flow-cytometry in acute myeloid leukemia. Such MRD monitoring strategy is applicable to virtually all AML patients with satisfactory sensibility (up to 10-4) but requires a high degree of expertise. Moreover, the actual leukemia-specificity of LAIPs has never been systematically questioned. We tried to address this issue by performing a comprehensive LAIP screening in bone marrow specimens from 12 healthy controls. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Matteo Piccini, Arianna Fani Source Type: research

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
In this study, we evaluated the anti-leukemia effects of concomitant BCL-2 and MAPK blockade by venetoclax in combination with MEK1/2 inhibitor GDC-0973 (cobimetinib). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Lina Han, Qi Zhang, Ce Shi, Antonio Cavazos, Vivian R. Ruvolo, Joel D. Leverson, Monique Dail, Darren C. Phillips, Jun Chen, Sha S. Jin, Rodrigo Jacamo, Naval Daver, Elias Jabbour, Hagop M. Kantarjian, Michael Andreeff, Deepak Sampath, Marina Konopleva Source Type: research

Age Does Not Adversely Influence Outcomes among Patients Older than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a successful treatment modality for AML and MDS. Information on transplant outcomes among older patients is limited because of concern of adverse transplant-related mortality (TRM) and poor overall survival (OS). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Dipenkumar Modi, Abhinav Deol, Seongho Kim, Lois Ayash, Asif Alavi, Marie Ventimiglia, Divaya Bhutani, Voravit Ratanatharathorn, Joseph Uberti Source Type: research